Background. A pre-morbid 'baseline' creatinine is required in order to diagnose and stage acute kidney injury (AKI) using the RIFLE classification. Estimation of baseline creatinine by solving the Modification of Diet in Renal Disease (MDRD) equation assuming a glomerular filtration rate of 75 ml/min/1.73 m 2 has been widely used but never validated. Methods. We analysed four cohorts of intensive care unit (ICU) patients from three centres (two from Pittsburgh and one from Mayo and Austin). Three cohorts consisted of preselected patients without AKI (Pittsburgh 1 n = 1048, Mayo n = 737, Austin n = 333), and measured creatinine values in these cohorts were taken to represent baseline creatinine values. The last cohort (Pittsburgh 2 n = 468) consisted of unselected ICU patients with baseline creatinine values recorded within 1 year before ICU admission. Using the Pittsburgh 1 cohort, we derived an equation using the same anthropometric variables as the MDRD equation: baseline creatinine = 0.74 − 0.2 (if female) + 0.08 (if black) + 0.003 × age (in years). We then compared measured creatinine in the Mayo and Austin cohorts and recorded creatinine in the Pittsburgh 2 cohort to the estimated creatinine from: (i) the MDRD equation; (ii) our new equation; (iii) a genderfixed creatinine of 0.8 mg/dl for females and 1.0 mg/dl for males.
Introduction
Acute kidney injury (AKI) is a common condition in critical illness and is associated with a significantly increased risk of death. AKI is classified using RIFLE criteria [1] ; although a slight modification has been recently proposed [2] . RIFLE classification provides three grades of increasing severity of AKI (Risk, Injury, Failure) and two outcome classes (Loss, End-stage kidney disease). The severity grades for AKI are based either on urine output or changes in serum creatinine from baseline. However, many patients may present with an elevated creatinine but without any baseline measure of renal function. When they initially proposed the RIFLE criteria, the Acute Dialysis Quality Initiative (ADQI) also proposed that, for patients without recognized chronic kidney disease, an estimated baseline creatinine could be obtained by solving the four-variable Modification of Diet in Renal Disease (MDRD) equation for a 'low normal' glomerular filtration rate (GFR) of 75 ml/min/1.73 m 2 [1] . Although this approach has been used in prior studies [3, 5, 6, 8, 9, 12, 13, 16, 17] , it has never been validated.
As of 2008, more than 200 000 patients have been screened and evaluated for AKI using the RIFLE criteria [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . A substantial number of the larger studies evaluating AKI have relied on the creatinine criteria (while the measurements of urine output were not available), and the majority of these studies used the calculated estimates of baseline creatinine to apply the RIFLE classification (see Table 1 .). Hence, most current data concerning AKI defined by RIFLE criteria are based on the assumption that baseline creatinine for respective patients could be estimated by solving the MDRD equation using a 'low normal' GFR of 75 ml/min/1.73 m 2 . However, this assumption may not be valid. The MDRD formula was derived from a population of outpatients with renal disease [19] . It is considered to perform poorly in patients with GFR above 60 ml/min/1.73 m 2 [20] , in severely ill hospitalized patients [21] and in malnourished patients [22] . There are few data showing the results of GFRs (either determined by estimation equations or direct measurement) in critically ill patients.
Thus, we sought to test the performance of the MDRDbased approach and explore alternative methods of estimating unknown baseline creatinine using data from three geographically distinct cohorts of critically ill patients.
Subjects and methods

Sources of data
Derivation set: Using a previously published database [13] from the University of Pittsburgh Medical Center, we constructed a cohort of patients with creatinine values within the normal range (using the definition of 'normal range' according to the manufacturer of the creatinine assay used in Pittsburgh centre, or s-creatinine <1.5 mg/dl for males, s-creatinine <1.2 mg/dl for females) and not changing more than 0.2 mg/dl (serum creatinine in milligram per decilitre may be converted to micromole per litre by multiplying by 88.4) or 30%, whichever is larger, during the ICU stay (n = 1048). Thus, by definition, these patients did not have AKI by creatinine criteria (increase in serum creatinine <0.3 mg/dl and/or by 50%), and their measured creatinine values were taken to represent the baseline creatinine values.
Validation set 1: Using the same criteria, we constructed two new cohorts including patients admitted between 1 January and 31 December 2006; one cohort from the Mayo Clinic (Rochester, Minnesota) (n = 737) and the other from Austin Hospital (Melbourne, Australia) (n = 333). Moreover, a prospectively created 'unselected' cohort of ICU patients from the Pittsburgh Medical Center with baseline creatinine values (n = 468) 'recorded' within 1 year before ICU admission was included as validation set 2.
Estimation methods
To predict the baseline creatinine value, three estimation methods were tested: Firstly, ('MDRD-based estimation method') we solved the MDRD formula for GFR 75 ml/min/1.73 m 2 as suggested by ADQI: Secondly, ('three-variable equation') using the same demographic and anthropometric variables included in MDRD formula (i.e. gender, age and race), we derived from the Pittsburgh non-AKI cohort (derivation set) by means of multivariable linear regression analysis the following equation:
Serum creatinine = 0:74−0:2 ðif femaleÞ + 0:08 ðif blackÞ + 0:003 × age ðin yearsÞ Thirdly, we tested an 'average gender-fixed creatinine' (derived from the entire non-AKI cohort) of 1.0 mg/dl for males and 0.8 mg/dl for females.
Bias, precision and accuracy
Mean relative error and absolute error were used as indices of bias and precision of the estimates. Relative error was calculated as the estimate minus RIFLE severity grades are based on the 'multiplication' (by a factor of 1.5, 2 or 3) of the baseline creatinine values. Whenever the estimated baseline creatinine value is 'lower' than the real (but unknown) baseline, the level (or presence) of AKI tends to be 'overestimated'. Conversely, whenever the estimated baseline is 'higher' than the real baseline, the level (or presence) of AKI could be 'underestimated'. Because of the multiplicative principle of RIFLE classification, it is convenient to think in terms of the 'ratio' between the estimated and real baseline creatinine value. If estimated/measured creatinine is <1/2 (0.5), 2/3 (0.66) or <3/4 (0.75), a false positive AKI of the RIFLE severity class F, I or R, respectively, will occur. Whenever the estimated/measured ratio is more than 1, 4/3 (1.33) or 2, a false negative corresponding to R, I and F occurs. Any systematical bias in the prediction of the baseline function could be thus transformed in a systematical error of the RIFLE classification. Thus, we evaluated the theoretical accuracy of the RIFLE criteria based on the estimated creatinine values as the percentage of ratios between the estimated and measured creatinine values (estimated baseline creatinine/measured baseline creatinine) within predetermined intervals of 0.75-1.0 and (0.66-1.33). These intervals ensure that subsequent RIFLE classification would not miss any patient with at least 1.5-or 2-fold increase from their true baseline nor ascribe AKI (grade Risk or more, or Injury or more) to any patients with a creatinine increase of <1.5-and 2-fold. Patients with ratios <0.75 were considered false positive for AKI and >1.00 falsely negative for AKI.
Determination of plasma creatinine
Plasma concentrations of creatinine were determined in Pittsburgh by an enzymatic assay (Vitros 950), in Mayo Clinic by an enzymatic assay (Roche/Hitachi 747) and in Austin Hospital by Jaffe colorimetric method (Beckman Synchron LX).
Re-calibration of original creatinine values to isotope-dilution mass spectrometry-traceable values
To enable comparison between centres, we recalibrated the measured creatinine values to isotope-dilution mass spectrometry (IDMS)-traceable values using creatinine standardization correlation equations provided by the manufacturer of the respective assays. We have also checked these re-calibration equations by externally available data [32, 33] 
Statistical evaluation
The central tendency for continuous data is expressed as the mean ± standard deviation or the median (interquartile range). We tested continuous variables for normality by distribution plots and the KolmogorovSmirnov test. We compared means using the Student's t-test when normally distributed, and the Mann-Whitney U-test when not. Comparisons across multiple groups were performed using the F-test, with Bonferroni correction for multiple comparisons. When data were not normally distributed, we used the Kruskal-Wallis H analysis of variance test. Chisquare test was used to compare categorical outcomes between groups. A value of P < 0.05 was considered significant. In order to develop an estimation method based on the available anthropometric values, we used both stepwise and simultaneous multivariable linear regression analysis. All analyses were performed on a statistical computer package (SPSS version 15, Illinois, USA). 
Results
Descriptive statistics
Patient characteristics of the derivation and validation datasets are shown in Table 2 . Both the mean creatinine value and the mean MDRD-GFR differed significantly between centres. After indirect recalibration efforts, the difference between these mean values persisted or even increased.
Blacks were under-represented in the Pittsburgh cohorts and virtually absent in the cohorts from Mayo and Austin hospital.
Bias of the estimates
Median relative error and accuracy (percentage of acceptably accurate estimates) of the estimation methods for particular age quartiles are shown in Table 3a . As indicated, none of the estimation methods performed equally across all age groups. However, Method i (MDRD-based) was most heavily biased by age, overestimating the level of serum creatinine by almost 40% in the young (below 25 years). Although the relative errors of Method i (MDRDbased) and ii (three-variable equation) were slightly (but statistically significantly) different between both genders (see Table 3b ), and the relative error of Method ii and iii (gender-fixed creatinine) between black and other races (see Table 3c ), these biases rarely translated into significant differences in respective accuracies. The relative error was significantly different (P < 0.005) for all the tested methods when applied across centres (see Table 4 ).
Precision and accuracy of the estimates
The median absolute error of the estimates was of the order of 0.1-0.2 mg/dl using any of the three methods (see Tables 3a, 3b , 3c and 4). As shown in Table 4 , the frequency of estimates sufficiently accurate to prevent ascribing false negative and false positive AKI according to RIFLE (using all severity grades including Risk) was rather low and in most occasions, <50%. When the definition of AKI was limited to the severity grades of Injury and Failure, all three methods were able to generate 78-90% reliable results for preselected normal range cohorts, and 63-70% for the unselected cohort of ICU patients. Overall, in terms of accuracy and precision, Method ii performed slightly better than Method i and iii.
Discussion
The primary finding of our study is that the methods used to ascertain the baseline creatinine have an important impact on subsequent detection and classification of AKI. We found that significant variation exists between centres in terms of mean serum creatinine values for patients, and this fact limits a generalizable method of estimating the baseline serum creatinine when it is unavailable. Most laboratories report values that deviate substantially from reference methods like IDMS [23] . Therefore, attention to the problems arising from inter-laboratory calibration differences must be taken into account in using any method estimating unknown baseline creatinines. To overcome the problem of inter-laboratory creatinine assay calibration differences, we asked the manufacturers of the respective assays to provide the IDMS standardization graphs and recalibration equations. The parameters of the recalibration equations were checked by externally available information [24, 25] and found to fit well. It was beyond the scope of our study to perform direct comparison of the assays. However, even after recalibration, significant differences in terms of mean serum creatinine values between centres persisted or even increased. These results suggest either a failure of the indirect calibration efforts or real differences between cohorts. Neither the use of IDMS-recalibrated creatinine values or 're-expressed' versions of the MDRD formula or the newly derived equation helped to overcome centre-specific bias.
Serum creatinine was chosen by the ADQI investigators as the main reference measure of kidney function, along with urine output, because it is readily available in clinical practice, and no better substitute is currently available. However, reliable information on baseline serum creatinine may not be available as many patients may have no previous creatinine measurement. This may be especially true in studies using large hospital databases. Furthermore, even if a previous creatinine can be found, if it was measured in the remote past, or by a different laboratory, the value may be influenced by progression of chronic disease, change in the muscle mass or different calibration of the creatinine assay. Because AKI may be present at admission (according to one study [13] , 22% of patients had AKI at ICU admission), the initial creatinine values are also unreliable measures of baseline renal function. Since serum creatinine level reflects mainly the balance of creatinine released from the skeletal muscle and that removed by the kidneys, any estimation method should include variables generally accepted to determinate kidney function or muscle mass. However, even when all the traditional factors are known, estimation of creatinine level may be quite inaccurate. In the study by McDonald [26] on 77 patients with chronic kidney disease (CKD), even when GFR was measured by inulin clearance, age, gender, weight and height were known, just 60% of the variance in the creatinine level was explained (R² = 0.6), and among these factors directly measured GFR accounted for >2/3 of their total predictive value. Even though this may not necessarily apply to patients without CKD, our data support the low level of correlation between measured and estimated creatinine values by any known method. We found that the mean MDRD-GFR of ICU patients without AKI or CKD is significantly >75 ml/min/1.73 m 2 and decreases steadily with age (by about 0.8 ml/min/ 1.73 m 2 per year). This is in good agreement with most population based studies indicating that GFR decreases by 0.4-1 ml/min/1.73 m 2 per year of age [26] [27] [28] [29] [30] . Accordingly, unless the GFR value used in MDRD equation is corrected for age, significant systematical age-dependent bias ensues such that AKI is 'underestimated' in younger patients, and possibly 'overestimated' in the elderly. In adults, serum creatinine in an individual is relatively stable over time, while the age-dependent decrease in GFR is paralleled by a decrease in muscle mass and increase in creatinine excretion. The gender-fixed approach, thus, was less biased by age and in terms of accuracy and precision performed similarly as compared to the MDRD-based approach. When comparing precision and accuracy of the estimates, the results obtained by the three-variable equation performed better than the MDRD-based estimates across all validation sets. However, it is questionable, whether the demonstrated differences in terms of accuracy and precision represent meaningful improvement. Indeed, none of the alternative methods offered a consistent improvement in accuracy compared to MDRDbased estimates.
A caveat to our study may be the fact that, as a reference for baseline creatinine in the derivation and one of the validation sets, we have taken the measured values from ICU patients with stable, normal range creatinine, and not from the recorded baselines of all ICU patients. To check for the effect of this selection bias, we used a second validation cohort consisting of unselected ICU patients with available recorded 'baseline' creatinines. This second validation cohort contained 16% of patients with baseline creatinines outside normal range and was simulating more real-life conditions. Although a cohort restricted to recorded serum creatinine levels may be biased towards more frequent chronic illness or increased number of medical encounters, this cohort nevertheless includes patients with a more realistic spectrum of underlying illness (e.g. with CKD) and risk for AKI.
Very recently, Bagshaw et al. [31] analysed the difference in 'overall' occurrence of respective RIFLE classes in patients with severe AKI (by other definition) when using measured or estimated creatinines. In contrast, we sought to evaluate how estimates may bias RIFLE classification in 'each individual' ICU patient. Although our approach is somewhat artificial (by simulating what would happen if AKI developed in patients who in reality had not met RIFLE creatinine criteria for AKI) and subject to the above-mentioned selection bias, we believe it could add further insights into the problem.
In conclusion, we believe that any method to estimate unknown baseline creatinine solely from anthropometric variables is likely to be of limited accuracy particular when AKI is mild-Risk only. We recommend that, whenever possible, baseline values should be obtained from prior laboratory testing. If recorded serum creatinine values are not available, the MDRD-based estimates can be used as a reference of baseline. However, case identification by the Risk, Injury, Failure, Loss, End-stage kidney disease (RIFLE) criteria classification may be inaccurate for patients in the Risk stratum. Therefore, results of studies using MDRD-based estimated baseline creatinine should be interpreted with caution especially for patients with mild AKI.
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